N/A N=44 Functional Exercise and Nutrition Education Program for Older Adults
Chronic Disease · Frail · Diabetes Mellitus
Primary: Feasibility - Recruitment — 9; 15; 9; 11 # of participants @ start of study
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=280 The SHUNT-V Study for Varices
Chronic Liver Disease
Primary: Disease Severity Index (DSI) Less Than/Equal to 18.3 to Rule Out Large Varices — 33; 3; 171; 68 Participants
N/A N=118 Using Tests in Preschool Children With Wheeze to Determine the Need for Inhaled Corticosteroid Therapy.
Wheezing
Primary: Wheeze Attacks — 1 Wheeze attacks
N/A N=194,238 Patient Portal Flu Vaccine Reminders_RCT 5 (LADHS)
Influenza · Respiratory Tract Infections
Primary: Receipt of the Annual Influenza Vaccine Among Adult and Pediatric Index Patients — 4641; 4629; 120137 Participants
Phase 4 N=16 Milk-Only Lactation Study to Evaluate the Concentration of Bempedoic Acid and Bempedoic Acid/Ezetimibe Fixed Combination Drug Product (FCDP) in the Breast Milk of Healthy Lactating Women
Healthy Lactating Women
Primary: Daily Infant Dose — 0.0331; 0.0337; 0.0002 Milligrams per day
N/A N=107 Testing Preliminary Effectiveness of a Community Health Worker (CHW) Training Program on Caregiving
Caregiver Burnout
Primary: Knowledge Pretest — 79.84; 84.94 score on a scale — p=0.26
N/A N=40 Prophylactic Application of an Incisional Wound Vac to Prevent Wound Complications in Obese Spine Surgery Patients
Spine Surgery · Wounds Vac
Primary: Count of Patients With Post Operative Infection — 4; 2; 5; 3 Participants
Phase 2 N=20 Hydroxychloroquine to Increase Tumor Suppressor PAR-4 Levels in Oligometastatic Prostate Cancer
Prostate Cancer Recurrent
Primary: Participants With Greater Than or Equal to 50% Induction in Serum PAR4 Levels — 11 Participants
Phase 1 N=45 Safety, Tolerability, and Immunogenicity Study of Sm-p80 + GLA-SE (SchistoShield(R)) Vaccine in Healthy Adults
Schistosomiasis
Primary: Number of Participants Reporting Serious Adverse Events (SAEs) Throughout the Study — 0; 0; 0; 0 Participants
N/A N=36 Reducing Use of Sleep Medications Assisted by a Digital Insomnia Intervention
Insomnia
Primary: Insomnia Severity Index (ISI) Change — 14.63; 6.13; 7.17 score on a scale — p=<0.001
Phase 3 N=481 An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)
Carcinoma, Non-Small-Cell Lung
Primary: Number of Patients With Adverse Events According to Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 — 478 Participants
N/A N=140 Safe and Timely Antithrombotic Removal - Ticagrelor (STAR-T)
Hemorrhage, Surgical · Blood Loss, Surgical · Blood Loss, Postoperative
Primary: Incidence of Perioperative (Periop) Bleeding, Primary Effectiveness Composite Endpoint, Modified Intent to Treat (mITT) Population — 2103; 2244 number of wins — p=0.748
Early Phase 1 N=13 Dopamine Receptor Contributions to Prediction Error and Reversal Learning in Anorexia Nervosa
Anorexia Nervosa
Primary: Measurement of Brain Activation (Measured in Percent Signal Change) During a Prediction Error Taste Reward Task Using Functional Magnetic Resonance Imaging (fMRI)…
N/A N=388 Survey of Cabozantinib Used To Treat People With Renal Cell Carcinoma
Renal Cell Carcinoma
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAE) — 216; 46; 73; 28 Participants
N/A N=10 Home Operations Utilizing Stimulation
Cognitive Performance
Primary: System Usability Scale — 46.25; 10 score on a scale